Tauriga Sciences Inc. Generates Record Quarterly Revenue for its 2nd Fiscal Quarter 2022
NEW YORK, NY, Oct. 01, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, today announced that it has generated record more...
Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at the 36th Annual Meeting of the Society for Immunotherapy of Cancer
HEIDELBERG, Germany, Oct. 01, 2021 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that three abstracts with preclinical data more...
Turtle Beach (HEAR) Arm, Oakley Tie-Up for Gaming Eyewear Collection
Turtle Beach Corporation ’s HEAR brand, ROCCAT, has collaborated with a leading sports equipment company — Oakley — to unveil a limited-edition PC gaming headset-compatible eyewear collection. Dubbed Oakley x ROCCAT Collection, the avant-garde eyewear more...
aTyr Pharma Announces Poster Presentation at the Society for Immunotherapy of Cancer Annual Meeting
SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company more...
Aravive to Present New Preliminary Data from Phase 1b Trial Evaluating AVB-500 in Clear Cell Renal Cell Carcinoma at 2021 Society for Immunotherapy of Cancer Annual Meeting
HOUSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that new preliminary safety, pharmacokinetic, pharmacodynamic, and clinical activity data from more...
Immutep to Present Phase II TACTI-002 Data at SITC 2021
Sydney, Australia, Oct. 01, 2021 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to more...
CymaBay Therapeutics Announces Presentations at The Liver Meeting® 2021
NEWARK, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced more...
Celyad Oncology to Present New Data on Allogeneic CAR T Therapy Program at the Society for Immunotherapy of Cancer Annual Meeting
Conference to take place both in-person in Washington D.C. and virtually November 10-14, 2021 MONT-SAINT-GUIBERT, Belgium, Oct. 01, 2021 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on more...
1933 Industries Announces AGM Date and Management Appointments
VANCOUVER, BC / ACCESSWIRE / October 1, 2021 / 1933 Industries Inc. (the “Company” or “1933 Industries“) (CSE:TGIF)(OTCQB:TGIFF), a Nevada focused cannabis consumer packaged goods company, announces that it will hold its Annual General and more...
Biofrontera reports preliminary approximate revenues for the month of September 2021
Leverkusen, Germany, Oct. 01, 2021 (GLOBE NEWSWIRE) — Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of September 2021. The Company’s more...